HALISTER: Glaxo 1Q Core EPS, Oper Profit Beat Estimates as Drug Sales Rise

Glaxo 1Q Core EPS, Oper Profit Beat Estimates as Drug Sales Rise

(Bloomberg) -- Co. now sees FY16 core EPS percentage growth to be 10%-12% at constant FX; had seen double-digit core EPS growth for 2016 at constant FX.
  • 1Q turnover: GBP6.23b vs est. GBP6b
  • 1Q core EPS 19.8p vs est. 17.9p
  • 1Q core oper profit GBP1.56b vs est. GBP1.43b
  • Statement
  • Conf. call at 2pm U.K. time; +44 20 7365 4163, password: 79183578
  • NOTE: Earlier, PREVIEW GLAXO 1Q: FX to Be Bright Spot Amid Respiratory Pressure
Alert: HALISTER
Source: BFW (Bloomberg First Word)

Tickers
GSK LN (GlaxoSmithKline PLC)

To de-activate this alert, click here

UUID: 7947283